AVTE
Price:
$2.68
Market Cap:
$506.68M
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Industry
Biotechnology
IPO Date
2021-06-30
Stock Exchange
NASDAQ
Ticker
AVTE
According to Aerovate Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -51.34%. This represents a change of 285.99% compared to the average of -13.30% of the last 4 quarters.
The mean historical ROE of Aerovate Therapeutics, Inc. over the last ten years is -96.53%. The current -51.34% ROE has changed -46.82% with respect to the historical average. Over the past ten years (40 quarters), AVTE's ROE was at its highest in in the March 2025 quarter at -3.36%. The ROE was at its lowest in in the June 2024 quarter at -26.25%.
Average
-96.53%
Median
-54.82%
Minimum
-326.79%
Maximum
-13.32%
Discovering the peaks and valleys of Aerovate Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 205.16%
Maximum Annual ROE = -13.32%
Minimum Annual Increase = -95.92%
Minimum Annual ROE = -326.79%
| Year | ROE | Change |
|---|---|---|
| 2025 | -38.32% | -57.94% |
| 2024 | -91.10% | 32.03% |
| 2023 | -69.00% | 69.77% |
| 2022 | -40.64% | 205.16% |
| 2021 | -13.32% | -95.92% |
The current ROE of Aerovate Therapeutics, Inc. (AVTE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-66.14%
5-year avg
-50.47%
10-year avg
-96.53%
Aerovate Therapeutics, Inc.’s ROE is less than IGM Biosciences, Inc. (16.11%), less than Quince Therapeutics, Inc. (1.82%), greater than Landos Biopharma, Inc. (-61.86%), greater than Berkeley Lights, Inc. (-55.98%), greater than enVVeno Medical Corporation (-66.39%), greater than Surface Oncology, Inc. (-61.52%), less than Insight Molecular Diagnostics Inc. (380.80%), less than Reneo Pharmaceuticals, Inc. (0%), greater than Miromatrix Medical Inc. (-74.80%), greater than Achilles Therapeutics plc (-41.05%),
| Company | ROE | Market cap |
|---|---|---|
| 16.11% | $77.50M | |
| 1.82% | $5.01M | |
| -61.86% | $71.68M | |
| -55.98% | $86.61M | |
| -66.39% | $173.94K | |
| -61.52% | $65.08M | |
| 380.80% | $142.80M | |
| 0% | $60.84M | |
| -74.80% | $92.95M | |
| -41.05% | $60.83M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aerovate Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aerovate Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aerovate Therapeutics, Inc.'s ROE?
How is the ROE calculated for Aerovate Therapeutics, Inc. (AVTE)?
What is the highest ROE for Aerovate Therapeutics, Inc. (AVTE)?
What is the 3-year average ROE for Aerovate Therapeutics, Inc. (AVTE)?
What is the 5-year average ROE for Aerovate Therapeutics, Inc. (AVTE)?
How does the current ROE for Aerovate Therapeutics, Inc. (AVTE) compare to its historical average?